drugset / Trial / NCT07237230

Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia

NCT07237230 ↗

Recruiting 40 enrolled Donghua Zhang
NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated clinical trial evaluating the safety and efficacy of allogeneic γδ T cell infusion for relapse prevention in high-risk acute myeloid leukemia patients after transplantation.

Timeline

Start
2025-07-01
Primary completion
2028-07-01
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject allogeneic γδ T cell infusion Cell therapy — —